CN106798786A - 蛹虫草玛卡压片及其制备方法 - Google Patents
蛹虫草玛卡压片及其制备方法 Download PDFInfo
- Publication number
- CN106798786A CN106798786A CN201710161175.4A CN201710161175A CN106798786A CN 106798786 A CN106798786 A CN 106798786A CN 201710161175 A CN201710161175 A CN 201710161175A CN 106798786 A CN106798786 A CN 106798786A
- Authority
- CN
- China
- Prior art keywords
- parts
- cordyceps militaris
- agate card
- compressing tablet
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001264174 Cordyceps militaris Species 0.000 title claims abstract description 50
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 24
- 244000068988 Glycine max Species 0.000 claims abstract description 17
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 16
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 16
- 240000000249 Morus alba Species 0.000 claims abstract description 15
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 15
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 14
- 244000235659 Rubus idaeus Species 0.000 claims abstract description 14
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 14
- 239000009636 Huang Qi Substances 0.000 claims abstract description 13
- 241000522254 Cassia Species 0.000 claims abstract description 12
- 244000241872 Lycium chinense Species 0.000 claims abstract description 12
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 8
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000227 grinding Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 235000002710 Ilex cornuta Nutrition 0.000 claims 1
- 241001310146 Ilex cornuta Species 0.000 claims 1
- 244000241838 Lycium barbarum Species 0.000 claims 1
- 235000015459 Lycium barbarum Nutrition 0.000 claims 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 241001247821 Ziziphus Species 0.000 description 11
- 206010029164 Nephrotic syndrome Diseases 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 235000019082 Osmanthus Nutrition 0.000 description 2
- 241000333181 Osmanthus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- -1 galactolipin Chemical compound 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010049589 Afterbirth pain Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 206010038423 Renal cyst Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000026475 palpebral edema Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229960003487 xylose Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种蛹虫草玛卡压片,其由活性组分和医学上可接受的辅料组成,其特征在于,所述活性组分由以下原料组成:以质量份数计,蛹虫草5~9份、玛卡5~8份、覆盆子7~11份、枸杞子6~10份、肉桂1~2份、龙眼3~8份、桑椹8~12份、黑豆4~8份、红枣4~8份、黄芪4~8份、黑东革阿里2~5份,各所述活性组分相互配合使所述蛹虫草玛卡压片具有良好的养肾强身效果。另外,本发明还提供所述蛹虫草玛卡压片的制备方法,该制备方法简单,易操作,具有广阔的应用前景。
Description
技术领域
本发明属于保健品领域,具体地,涉及一种蛹虫草玛卡压片及其制备方法。
背景技术
肾病综合症根据发病病因可分为原发性和继发性两大类,原发性肾病综合症是原发性肾小球疾病最常见的临床表现而继发性肾病综合症的原因比较多,常见的有糖尿病肾病、系统性红斑狼疮性肾炎、感染及药物等引起的肾病综合症;原发性肾病综合症的病理类型也比较多,有微小病变性肾病、局灶节段性、膜性肾病等。中医认为,肾病综合症的发生发展与病人的烦劳过度、先天不足或久病失治误治、体虚感邪以及饮食不节、情志劳欲调节失常等诱因有关,这些诱发原因可使肺、脾、肾三脏功能失调,引起脏腑气血阴阳不足,导致人体内水液代谢紊乱,水湿停聚,精微外泻而成本病;肾综发展到后期,肺、脾、肾三脏都成虚的病理表现,使精微物质更加外泻,肾虚加重,正气愈虚邪气愈盛,就会发生“癃闭”“关格”等也就是尿毒症的表现,到了此时,治疗难度增加,如治疗不当,随时都会危及病人的生命。因此,开发一种能够养肾的保健药品进行养肾强身具有深远的意义。
发明内容
有鉴于此,本发明提供一种蛹虫草玛卡压片及其制备方法,以解决上述问题。
具体地,本发明采取如下技术方案:
一种蛹虫草玛卡压片,其由活性组分和医学上可接受的辅料组成,所述活性组分由以下原料组成:以质量份数计,蛹虫草5~9份、玛卡5~8份、覆盆子7~11份、枸杞子6~10份、肉桂1~2份、龙眼3~8份、桑椹8~12份、黑豆4~8份、红枣4~8份、黄芪4~8份、黑东革阿里2~5份。
基于上述的蛹虫草玛卡压片,所述活性组分由以下原料组成:以质量份数计,蛹虫草6~8份、玛卡5~8份、覆盆子8~10份、枸杞子7~9份、肉桂1~2份、龙眼4~6份、桑椹9~11份、黑豆5~6份、红枣5~6份、黄芪5~6份、黑东革阿里3~4份。
其中,所述蛹虫草中的虫草素,可抗病毒、抗菌、明显抑制肿瘤生长、干扰人体RNA及DNA合成;蛹虫草富含虫草酸,虫草酸能有效预防治疗脑血栓、脑溢血、肾功能衰竭,同时还具有利尿作用;蛹虫草中的腺苷,可以抗病毒、抗菌,抑制血小板积聚防治血栓形成,还可消除面斑,抗衰防皱;蛹虫草中虫草多糖,有提高免疫力,延缓衰老,扶正固本,保护心脏、肝脏,抗痉的作用;蛹虫草中的麦角甾醇、超氧化物歧化酶,对抑制或消除催人衰老的超氧自由基形成及抗癌、防衰、减毒有良好作用;蛹虫草还富含硒,可以明显地抑制癌细胞的生长,刺激免疫球蛋白和抗体的产生,增强机体免疫和抗氧化能力。中医认为,虫草入肺肾二经,既能补肺阴,又能补肾阳,主治肾虚,阳萎遗精,腰膝酸痛,病后虚弱,久咳虚弱,劳咳痰血,自汗盗汗等,是唯一的一种能同时平衡、调节阴阳的中药。
所述玛卡中氨基酸、矿物质锌、牛磺玛卡酸等成份能明显对抗疲劳;独有的生物活性物质玛卡烯、玛卡酰胺,利于勃起功能,提高精子数量和活跃能力,提高精子质量;玛卡的多种生物碱能调节肾上腺、胰腺、卵巢等功能,平衡体内的荷尔蒙水平,丰富的牛磺酸、蛋白质等能调理及修复生理机能,改善气血和缓解更年期症状。
所述覆盆子中的覆盆子油属于不饱和脂肪酸,可促进前列腺分泌荷尔蒙;中医认为其归肝、肾经,可以补肝益肾,固精缩尿,明目。
所述枸杞子可以明显的降血脂、调节脂类代谢功能,对预防心血管疾病具有积极作用;富含枸杞多糖,枸杞多糖是一种水溶性多糖,由阿拉伯糖、葡萄糖、半乳糖、甘露糖、木糖、鼠李糖这6种单糖成分组成,具有生理活性,能够增强非特异性免疫功能,提高抗病能力,抑制肿瘤生长和细胞突变,还可以增加睾丸、附睾的脏器系数,保护生殖系统。
所述肉桂,气厚,为纯阳之品,有温补肾阳,祛寒止痛,温通经脉,引火归元的功效,肉桂中还含有黄烷醇多酚类抗氧化物质,能提高胰岛素对血糖水平的稳定作用和降低胰岛素抵抗。
所述龙眼具有极强的清除自由基的能力,有抗辐射、预防心脑血管疾病、提高免疫力、延缓衰老等功效;桂圆含有大量的铁、钾等元素,能促进血红蛋白的再生以治疗因贫血造成的心悸、心慌、失眠、健忘;桂圆含铁及维生素比较多,可减轻宫缩及下垂感,对于加速代谢的孕妇及胎儿的发育有利,具有安胎作用;桂圆中含尼克酸高达2.5毫克(每100克),可用于治疗尼克酸缺乏造成的皮炎、腹泻、痴呆,甚至精神失常等.
所述药桑中含有多种营养物质,含糖量高,具有丰富的氨基酸,还含有酸、果胶、矿物质、胡萝卜素以及抗坏血酸素等,可以用于治疗因患肝硬化、脂肪肝、痢疾等病引起的营养不良症;另外,药桑性寒、无毒,有补肝肾、明目、生津、补血、祛风等药用价值,还具有防癌抗诱变、增强免疫力、保肾护肝、驻颜抗衰老、促进造血细胞生长、降低血糖血脂的保健功能,特别是药桑中含有一种叫白黎芦醇(RES)的物质,能刺激人体内某些基因抑制癌细胞生长,并能阻止血液细胞中栓塞的形成,阻止致癌物质引起的细胞突变,还可以能减轻多种因素造成的组织器官损伤,具有保护肝脏,抑制血小板聚集、镇咳平喘、抗菌、抗病毒、降血脂及抗脂质过氧化等作用。
所述黑豆中富含有蛋白质、脂肪、维生素、微量元素等多种营养成分,同时又具有多种生物活性物质,如黑豆色素、黑豆多糖和异黄酮等。黑豆中所含的不饱和脂肪酸,可促进胆固醇的代谢、降低血脂,预防心血管疾病。据中医药理记述,黑豆具有消肿下气、润肺清热、活血利水、祛风除痹、补血安神、明目健脾、补肾益阴、解毒的作用;主要用于治疗水肿胀满、风毒脚气、黄疽浮肿、风痹痉挛、产后疼、口襟、痈肿疮毒,可解药毒,制风热而止盗汗,乌须黑发以及延年益寿的功能。
所述红枣能促进白细胞的生成,降低血清胆固醇,提高血清白蛋白,保护肝脏,红枣中还含有抑制癌细胞,甚至可使癌细胞向正常细胞转化的物质,还富含钙和铁,它们对防治骨质疏松、产后贫血有重要作用。
所述黄芪具有补气固表,利尿托毒,排脓,敛疮生肌的功效。用于治疗气虚乏力,食少便溏,中气下陷,久泻脱肛,便血崩漏,表虚自汗,痈疽难溃,久溃不敛,血虚萎黄,内热消渴。
所述黑东革阿里味苦,性凉,清热,截疟,利湿退黄,壮阳,能改善精子的质量,提高精子数量、大小和移动速度,黑东革阿里含有一种抗氧化酶,能抵制对身体有害的自由基产生的连锁反应。
一种上述蛹虫草玛卡压片的制备方法,其包括以下步骤:
预处理 将所述活性组分中的各原料中的杂物剔除,经精选、清洗、晾晒、干燥至含水率≤3%备用;
粗粉碎 将经过预处理的各原料分别用粗粉碎机粉碎,过80~140目筛备用;
超微粉碎 将粗粉碎后的各原料分别经超微粉碎得到各原料的超微细粉;
混配造粒 按上述的质量份,将各原料超微细粉混配均匀,然后加入所述辅料,并依次进行制粒、干燥、压片处理,即可制得所述蛹虫草玛卡压片。
与现有技术相比,本发明相对现有技术具有突出的实质性特点和显著的进步,具体的说,本发明提供的蛹虫草玛卡压片中的各种原料之间相互配合,协同作用,使其可以修复各种原因引起的肾功能异常,利于肾病综合症、肾功能不全、肾囊肿、肾炎、肾虚等肾病的恢复。同时,由于所述蛹虫草玛卡压片中的活性组分的原料均来源于药食同源的植物,所以不会对使用者的身体带来副作用,可以长时间使用,无毒副作用。此外,所述蛹虫草玛卡压片还可以提高人体免疫力、抗癌的功效,有利于高血压、高血脂等多种慢性病的恢复,使人体保持活力,远离亚健康。另外,本发明提供的所述蛹虫草玛卡压片的制备方法简单,易操作,适于大规模生产。
具体实施方式
下面通过具体实施方式,对本发明的技术方案做进一步的详细描述。
实施例1
本实施例提供一种蛹虫草玛卡压片,由以下组分构成:以质量份数计,蛹虫草5份、玛卡5份、覆盆子7份、枸杞子6份、肉桂1份、龙眼3份、桑椹8份、黑豆4份、红枣4份、黄芪4份、黑东革阿里2份、蜂蜜2份。
本实施例还提供所述蛹虫草玛卡压片的制备方法,其包括以下步骤:
预处理 将蛹虫草、玛卡、覆盆子、枸杞子、肉桂、龙眼、桑椹、黑豆、红枣、黄芪和黑东革阿里中的杂物剔除,经精选、清洗、晾晒、干燥至含水率≤3%备用;
粗粉碎 将经过预处理的蛹虫草、玛卡、覆盆子、枸杞子、肉桂、龙眼、桑椹、黑豆、红枣、黄芪和黑东革阿里分别用粗粉碎机粉碎,过80~140目筛备用;
超微粉碎 将粗粉碎后的蛹虫草、玛卡、覆盆子、枸杞子、肉桂、龙眼、桑椹、黑豆、红枣、黄芪和黑东革阿里分别经超微粉碎得到各组分的超微细粉;
混配造粒 按上述的质量份,将各所述组分超微细粉混配均匀,然后加入所述蜂蜜,并依次进行制粒、干燥、压片处理,即可制得所述蛹虫草玛卡压片。
实施例2
本实施例提供一种蛹虫草玛卡压片,本实施例与实施例1的不同之处在于,所述蛹虫草玛卡压片由以下组分构成:以质量份数计,蛹虫草9份、玛卡8份、覆盆子11份、枸杞子10份、肉桂2份、龙眼8份、桑椹12份、黑豆8份、红枣8份、黄芪8份、黑东革阿里5份。
本实施例还提供所述蛹虫草玛卡压片的制备方法,该制备方法同实施例1。
实施例3
本实施例提供一种蛹虫草玛卡压片,本实施例与实施例1的不同之处在于,所述蛹虫草玛卡压片由以下组分构成:以质量份数计,蛹虫草7份、玛卡6份、覆盆子9份、枸杞子7份、肉桂1份、龙眼5份、桑椹10份、黑豆5份、红枣7份、黄芪6份、黑东革阿里3份。
本实施例还提供所述蛹虫草玛卡压片的制备方法,该制备方法同实施例1。
实施例4
本实施例提供一种蛹虫草玛卡压片,本实施例与实施例1的不同之处在于,所述蛹虫草玛卡压片由以下组分构成:以质量份数计,蛹虫草8份、玛卡7份、覆盆子10份、枸杞子7份、肉桂1份、龙眼5份、桑椹9份、黑豆6份、红枣7份、黄芪5份、黑东革阿里4份。
本实施例还提供所述蛹虫草玛卡压片的制备方法,该制备方法同实施例1。
为了证明本发明提供的蛹虫草玛卡压片的保健作用,选择不同的受试人群各20人,食用实施例4提供的蛹虫草玛卡压片,每日1次,每次2片,观察90天。
1.受试人群:年龄在30~50岁之间,有轻微肾炎,常伴乏力、倦怠、腰酸、食欲不振、水肿时有时无,多为眼睑水肿,下肢凹陷性水肿。
90天后:肾炎痊愈,食欲明显增强,精神更加充沛,水肿情况减弱,食用过程中未发现不良反应。
2.受试人群:年龄在30~50岁之间,肾虚,伴随有四肢发冷,畏寒,头晕,腰酸背痛,记忆力下降。
90天后:肾虚症状明显好转,食用过程中未发现不良反应。
3.受试人群:年龄在50~70岁之间,长期的高血压、高血脂,常见头痛,头晕,胸闷气短,心情抑郁。
90天后:高血压、高血脂的症状有所缓解,头晕、头痛次数减少,心情更加开朗,食用过程中未发现不良反应。
4.受试人群:年龄在20~40岁之间,体检无异常、脱发、体弱多病、神疲乏力、经常感冒。
90天后:脱发有所缓解,神疲乏力感消除,精力充沛有活力,睡眠好,体质明显增强,免疫力增强,机体疲劳时间延后,食用过程中未发现不良反应。
最后应当说明的是:以上实施例仅用以说明本发明的技术方案而非对其限制;尽管参照较佳实施例对本发明进行了详细的说明,所属领域的普通技术人员应当理解:依然可以对本发明的具体实施方式进行修改或者对部分技术特征进行等同替换;而不脱离本发明技术方案的精神,其均应涵盖在本发明请求保护的技术方案范围当中。
Claims (3)
1.一种蛹虫草玛卡压片,其由活性组分和医学上可接受的辅料组成,其特征在于,所述活性组分由以下原料组成:以质量份数计,蛹虫草5~9份、玛卡5~8份、覆盆子7~11份、枸杞子6~10份、肉桂1~2份、龙眼3~8份、桑椹8~12份、黑豆4~8份、红枣4~8份、黄芪4~8份、黑东革阿里2~5份。
2.根据权利要求1所述的蛹虫草玛卡压片,其特征在于,所述活性组分由以下原料组成:以质量份数计,蛹虫草6~8份、玛卡5~8份、覆盆子8~10份、枸杞子7~9份、肉桂1~2份、龙眼4~6份、桑椹9~11份、黑豆5~6份、红枣5~6份、黄芪5~6份、黑东革阿里3~4份。
3.一种权利要求1或2所述蛹虫草玛卡压片的制备方法,其包括以下步骤:
预处理 将所述活性组分中的各原料中的杂物剔除,经精选、清洗、晾晒、干燥至含水率≤3%备用;
粗粉碎 将经过预处理的各原料分别用粗粉碎机粉碎,过80~140目筛备用;
超微粉碎 将粗粉碎后的各原料分别经超微粉碎得到各原料的超微细粉;
混配造粒 按权利要求1或2所述的质量份,将各原料超微细粉混配均匀,然后加入所述辅料,并依次进行制粒、干燥、压片处理,即可制得所述蛹虫草玛卡压片。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710161175.4A CN106798786A (zh) | 2017-03-17 | 2017-03-17 | 蛹虫草玛卡压片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710161175.4A CN106798786A (zh) | 2017-03-17 | 2017-03-17 | 蛹虫草玛卡压片及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106798786A true CN106798786A (zh) | 2017-06-06 |
Family
ID=58988325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710161175.4A Pending CN106798786A (zh) | 2017-03-17 | 2017-03-17 | 蛹虫草玛卡压片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106798786A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107259563A (zh) * | 2017-06-08 | 2017-10-20 | 山东瑞芝生物科技有限公司 | 一种养生保健品及制备方法 |
CN107361357A (zh) * | 2017-06-20 | 2017-11-21 | 苏州市李良济健康产业有限公司 | 一种抗癌的保健品的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104688797A (zh) * | 2015-03-19 | 2015-06-10 | 沈阳伊人宝生化制品有限公司 | 虫草玛咖片 |
CN105211761A (zh) * | 2015-08-14 | 2016-01-06 | 黄秀英 | 一种补肾健发糊 |
CN106421371A (zh) * | 2016-11-27 | 2017-02-22 | 山东华胶饮品有限公司 | 一种蛹虫草黄精片的配方及其制备方法 |
-
2017
- 2017-03-17 CN CN201710161175.4A patent/CN106798786A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104688797A (zh) * | 2015-03-19 | 2015-06-10 | 沈阳伊人宝生化制品有限公司 | 虫草玛咖片 |
CN105211761A (zh) * | 2015-08-14 | 2016-01-06 | 黄秀英 | 一种补肾健发糊 |
CN106421371A (zh) * | 2016-11-27 | 2017-02-22 | 山东华胶饮品有限公司 | 一种蛹虫草黄精片的配方及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107259563A (zh) * | 2017-06-08 | 2017-10-20 | 山东瑞芝生物科技有限公司 | 一种养生保健品及制备方法 |
CN107361357A (zh) * | 2017-06-20 | 2017-11-21 | 苏州市李良济健康产业有限公司 | 一种抗癌的保健品的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107929420A (zh) | 改善人体气血功能和提高免疫力的中药组合物和检测方法 | |
CN109966417A (zh) | 一种针对糖尿病人群的固体饮料 | |
CN105878764B (zh) | 一种蛹虫草冲剂及其制备方法 | |
CN106806643A (zh) | 一种治疗糖尿病的中药组合物 | |
CN103263012B (zh) | 一种药食同源的保健食品及其制备方法 | |
CN105079465A (zh) | 一种降低血糖的组合物 | |
CN102763873B (zh) | 天麻营养饮料及其生产工艺 | |
CN106798041A (zh) | 护肝强肾茶及其制备方法 | |
CN101946895B (zh) | 一种以泥鳅为主料的功能食品及其制备方法 | |
CN104739977A (zh) | 玛咖养生壮元酒(片) | |
CN111000252A (zh) | 一种减脂且营养均衡的代餐食品及其制备方法 | |
CN106798786A (zh) | 蛹虫草玛卡压片及其制备方法 | |
CN106387888A (zh) | 一种用于生产功能性食品、保健品和药品的组合物及制备方法 | |
CN103271356B (zh) | 一种增强免疫力、缓解体力疲劳组合物及其制备方法 | |
CN107596197A (zh) | 一种补气解郁茶及其制备方法 | |
CN107156820A (zh) | 全面调理女性产后受损体质的营养食品及其制备方法 | |
CN103340919B (zh) | 一种灵芝精粉复方软胶囊及其制备方法 | |
CN108721407A (zh) | 一种气阳两虚体质调理足浴粉及其制备方法 | |
CN101480471B (zh) | 一种治疗帕金森氏病的药物及其制备方法 | |
CN101524473B (zh) | 虫草抗癌长寿丹及其制备方法 | |
CN106579384A (zh) | 一种具有分解脂肪作用的综合酵素粉及其制备方法 | |
CN107198754A (zh) | 一种清除胃肠道毒素毒垢及保护肠道粘膜的中药组合物 | |
CN111418803A (zh) | 一种养生汤的配制方法 | |
CN105311375A (zh) | 一种降低血脂的组合物 | |
CN104365905A (zh) | 一种降血脂去火利尿养生茶及其生产方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170606 |
|
RJ01 | Rejection of invention patent application after publication |